PReS Lupus Working Party

International collaborative research group under PReS, focused on childhood-onset lupus #cSLE. Chaired by @EvemdSmith_eve #PedsRheum Join us!

[PReS Lupus Working Party @PReSLupusWP]

🌟 Just out! The 2026 BSR guideline on SLE #lupus has been published.
👏🏻 For the first time, it includes dedicated guidance for children and young people alongside adults. Check it out! ⬇️ #pedsrheum #cSLE

[Md Yuzaiful Md Yusof @Yuz6Yusof]

🚨Hot of the press in this heatwave. Our #BSR @RheumatologyUK Guideline on the Management of #lupus is out now! 🥳

Our Guideline:

✅Comprehensive
✅Life-course
✅Multidisciplinary
✅Evidence-based
✅Harmonise delivery of care

https://t.co/1egaExblVV

https://t.co/Wof8Ib3iiW

[PAFLAR AFRICA @paflar]

Join PAFLAR in yet another exciting webinar
Registration is free

The Paediatric Society of the African League against Rheumatism (PAFLAR) cordially invites you to an exclusive Special CME Webinar focusing on "Different by Design: Why Childhood Lupus Deserves Its Own Lens"

[Lupus Foundation of America @LupusOrg]

We're proud to announce Dr. Wobma from @HarvardMed as the 2026 Michael Jon Barlin Pediatric Lupus Research Grant recipient. Her study explores using CAR-Treg therapy for immune balance and achieving drug-free remission in children with #lupus.

Learn more: https://t.co/yfXxqeGu9P

[American College of Rheumatology @ACRheum]

Pediatric rheumatology is a dynamic field advancing research, clinical care, and advocacy. Hear more about what this specialty means to those who practice and help us celebrate 50 years of pediatric rheumatology. Explore the history, meet the pioneers and more → https://t.co/kMGheP23Hc

[American College of Rheumatology @ACRheum]

Meet the Greats of Pediatric Rheumatology: Dr. James T. Cassidy

Widely regarded as the “father of pediatric rheumatology,” Dr. James T. Cassidy helped establish pediatric rheumatology as a recognized subspecialty and shaped generations of clinicians through his leadership, teaching, and research. He authored the influential Textbook of Pediatric Rheumatology, which became a defining reference in the field, and published hundreds of scientific papers advancing the understanding and treatment of pediatric rheumatic diseases.

Beyond academic medicine, Dr. Cassidy championed education, mentorship, and patient-centered care. His legacy continues through initiatives including the James T. Cassidy Award, the Cassidy Conference, and Camp Jambalaya for children with rheumatic illnesses.

LEARN MORE about the history of pediatric rheumatology -> https://t.co/kMGheP23Hc

#50YearsOfPedsRheum

[EULAR @eular_org]

Missed a session or want to revisit your favourite highlights?

📺Access the #EULAR2026 Congress On-Demand and watch inspiring Scientific Sessions presented throughout the Congress, available from Monday 8 June until 31 December 2026!

Register here 👉 https://t.co/LZWAOj5ife

[PReS Lupus Working Party @PReSLupusWP]

🔎 New review by Ravelli et al. summarises two decades of literature on biologic therapies in #cSLE ➡️ covering current evidence, emerging therapies & the shift towards more personalised, steroid-sparing care for children with lupus #PedsRheum Check it out https://t.co/8KLzA2NSqs

[Autoinmunes Medicina Interna Parc Taulí @autoinMI_tauli]

The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus

⏩102 recommendations
⏩ diagnosis, monitoring, management

https://t.co/j9tD2ytjOy

[Md Yuzaiful Md Yusof @Yuz6Yusof]

🚨Hot of the press in this heatwave. Our #BSR @RheumatologyUK Guideline on the Management of #lupus is out now! 🥳

Our Guideline:

✅Comprehensive
✅Life-course
✅Multidisciplinary
✅Evidence-based
✅Harmonise delivery of care

https://t.co/1egaExblVV

https://t.co/Wof8Ib3iiW

[PReS Lupus Working Party @PReSLupusWP]

⏳ Countdown! Less than 3 months until we meet again at #PReS2026 for the Lupus WP Meeting 🇷🇸

Join us for the latest updates in paediatric #lupus research, with opportunities to connect and collaborate 🤝 #cSLE #pedsrheum

📅 16 September 2026 | 🕑 14:15–15:15

[Dr.Israrul Haque MD DM RhMSUS SCE (RCP, UK) @Haque_RheumAI]

Proud to be part of this multicentre study on the genetic landscape of early-onset SLE in India, highlighting the role of monogenic causes in pediatric lupus and the importance of genetic testing in early disease.

[ACR_Journals @ACR_Journals]

June A&R In This Issue
• Macrophage–Fibroblast Crosstalk Underlies Hip Pathophysiology
• Reduced-Intensity Stem Cell Transplant for SSc
• Distinct Epigenetic Subgroups in Childhood-Onset Lupus
🔎 Efficacy & Safety of Subcutaneous Anifrolumab in SLE: the TULIP-SC Study

https://t.co/sbtazCij52

[Lupus Hub @lupus_hub]

CONGRESS | #EULAR2026 | POSTER

Eve Smith shares cSLE-T2T-GLOBAL data validating pediatric T2T endpoints across the UK JSLE Cohort (n = 492), the CARRA Registry (n = 1,074), and the JIRcohort (n = 215) in childhood #SLE (N = 1,781).

• Across 12,915 visits and median 3.5 years follow-up, target attainment was achieved in 66.3% for cLLDAS, 54.1% for cCR, and 46.7% for cCR-0.
• Median time from first visit to target was 11.2 months for cLLDAS, 14.0 months for cCR, and 16.8 months for cCR-0.
• Being in cLLDAS at the previous visit was associated with lower subsequent high disease activity risk (HR, 0.29; p < 0.05).
• Greater time spent in cLLDAS was associated with progressively lower risk of subsequent high disease activity, with HRs of 0.67, 0.45, 0.30, and 0.20 for 20%, 40%, 60%, and 80% of follow-up time in target, respectively.
• Greater time spent in cLLDAS was also associated with progressively lower risk of new damage, with HRs of 0.70, 0.49, 0.34, and 0.24 for 20%, 40%, 60%, and 80% of follow-up time in target, respectively.

These data support cLLDAS as a pediatric T2T endpoint associated with reduced high disease activity and new damage risk in childhood SLE.

Follow our live feed for more updates: https://t.co/WXrVHDpHZI

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#RheumTwitter #rheumatology #MedNews #MedEd #MedicalCongress #lupus @UofGlasgow @RHCGlasgow @evemdsmith_eve

[sheila @RHEUMarampa]

TRM-SLE is a novel clinical outcome assessmentfor use in #SLE trials
8 domains: mucocutaneous, arthritis, hemolytic anemia, thrombocytopenia, nephropathy, serositis
Developed via multistage consensus process
Higher pt enrollment potential?
POS1068 @RheumNow #EULAR2026

[EMEUNET @EMEUNET]

Bridge, don’t ditch. Kabir Budlender, from the Netherlands, provides a brilliant talk about transition care. #EULAR2026 #eularEMEUNET #Rheumavision

[STRATA-FIT @STRATA_FIT]

An amazing presentation on access to healthcare and information for young adults with rheumatic diseases. Congratulations, Natasha!

#STRATAFIT #EULAR2026

@natasha_trehan @takeapaincheck

[Stephen Marks @kidskidneymarks]

Well done to Kyle Ying-kit Lin for prestigious oral abstract showing rituximab and rapid corticosteroid tapering effectively achieves and maintains remission in childhood-onset lupus nephritis: ERA Congress 2026 in Glasgow #ERA26 @BAPNnephrology @ERAkidney @SECGlasgow @GoshRenal

[Aurelie Najm @AurelieRheumo]

And we are on!
A full house for #EULAR2026 Opening ceremony highlighting @eular_org initiatives in the field of research, education and patient empowerment and a call “better care leading to better lives” by president Xenofon Baraliakos
@RheumNow

[EMEUNET @EMEUNET]

🎥 Meet Emiliano Marasco, one of the EMEUNET Top 10 Abstract winners at EULAR 2026! 📍 Don’t miss his presentation in London on Fri. 5 June 2026, 9.05-9.15, Connaught Room 3 &amp; 4!
#eularEMEUNET #emeunettop10abstracts #EULAR2026 congress

[PReS Lupus Working Party @PReSLupusWP]

🇬🇧 Attending #EULAR2026? 🎉Don’t miss the paediatric lupus sessions highlighted by our Working Party and let’s keep moving cSLE research forward 🌟
#pediatric #lupus #cSLE #childhood #PedsRheum